All In Biotech

Drug Trial Radar · NCT06671483

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,583 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,583

Actual

Start

Mar 3, 2025

Primary completion

May 18, 2027

Study completion Jan 28, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.

Conditions

  • Psoriatic Arthritis

Interventions

  • ZasocitinibDrug

    Zasocitinib over-encapsulated tablets.

  • Active ComparatorDrug

    Active comparator capsule.

  • PlaceboDrug

    Zasocitinib or active comparator matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 16 for Zasocitinib Dose A and B Compared to PlaceboTime frame: At Week 16

Locations

184 sites in 20 countries. Site status is shown where the registry gives one.

  • AARR- Chandler AZ

    Chandler, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ

    Phoenix, Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ

    Phoenix, Arizona

  • First OC Dermatology Research Inc.

    Fountain Valley, California

  • Purushotham & Akther Kotha MD

    La Mesa, California

  • Triwest Research Associates LLC

    La Mesa, California

  • The Cohen Medical Centers

    Thousand Oaks, California

  • Foothill Arthritis Clinic

    Tujunga, California

  • Medvin Clinical Research

    Whittier, California

  • Denver Arthritis Clinic | Denver, CO

    Denver, Colorado

  • Arthritis & Rheumatic Disease Specialties (AARDS)

    Aventura, Florida

  • RASF- Clinical Research Center

    Boca Raton, Florida

  • Clinical Research of West Florida | Clearwater, FL

    Clearwater, Florida

  • GNP Research, LLC | Hollywood, FL

    Cooper City, Florida

  • Driven Research LLC

    Coral Gables, Florida

  • Tectum Medical Research

    Davie, Florida

  • Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research

    Hialeah, Florida

  • Bioresearch Partners

    Miami, Florida

  • HMD Research LLC

    Orlando, Florida

  • Millennium Research | Ormond Beach, FL

    Ormond Beach, Florida

  • IRIS Research and Development | Plantation, FL

    Plantation, Florida

  • Sarasota Arthritis Research Center

    Sarasota, Florida

  • West Broward Rheumatology Associates, Inc.

    Tamarac, Florida

  • Clinical Research of West Florida | Tampa, FL

    Tampa, Florida

  • Marietta Rheumatology Associates

    Marietta, Georgia

  • GSCP/CIS

    Orland Park, Illinois

  • Greater Chicago Specialty Physicians LLC/CIS

    Schaumburg, Illinois

  • Accurate Clinical Research, Inc. | Lake Charles

    Lake Charles, Louisiana

  • Klein & Associates, M.D., P.A.

    Hagerstown, Maryland

  • Michigan Rheumatology Group, P.C. - Grand Blanc Office

    Grand Blanc, Michigan

  • Ash Research Clinic - Howell

    Howell, Michigan

  • June DO, PC Private Practice - Dr. Justus Fiechtner

    Lansing, Michigan

  • Clinical Research Institute of Michigan

    Saint Clair Shores, Michigan

  • Saint Louis Rheumatology

    St Louis, Missouri

  • Albuquerque Center for Rheumatology PC

    Albuquerque, New Mexico

  • Santa Fe Rheumatology

    Santa Fe, New Mexico

  • NYU Langone Health | Joseph S. and Diane H. Steinberg Ambulatory Care Center - Rheumatology Department

    Brooklyn, New York

  • Accellacare of Hickory

    Hickory, North Carolina

  • University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology Division

    Cleveland, Ohio

  • Paramount Medical Research & Consulting, LLC

    Middleburg Heights, Ohio

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.